Recursion Pharmaceuticals, Inc.

RXRX

$4.12

Name : Recursion Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,147,602,432.00

EPSttm : -1.84

Recursion Pharmaceuticals, Inc.

$4.12

0.48%

$0.02

Float Short %

31.15

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

0.01

EPS Last/This Y

0.16

EPS This/Next Y

0.33

Price

4.11

Target Price

6.33

Analyst Recom

2.43

Performance Q

-19.06

Relative Volume

0.6

Beta

0.98

Ticker: RXRX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	RXRX	6.68	0.21	0.15	422045
2025-10-21	RXRX	6.12	0.20	0.34	455272
2025-10-22	RXRX	5.73	0.21	0.19	472724
2025-10-23	RXRX	5.72	0.21	0.19	476180
2025-10-24	RXRX	6.03	0.21	0.10	486658
2025-10-27	RXRX	6.29	0.21	0.11	461029
2025-10-28	RXRX	5.91	0.20	0.25	485265
2025-10-29	RXRX	5.88	0.21	0.31	490378
2025-10-30	RXRX	5.63	0.21	0.33	499297
2025-10-31	RXRX	5.51	0.21	0.39	502017
2025-11-03	RXRX	5.43	0.22	0.44	462778
2025-11-04	RXRX	4.98	0.22	0.26	473202
2025-11-05	RXRX	4.95	0.23	0.19	482467
2025-11-06	RXRX	4.61	0.24	0.38	482391
2025-11-07	RXRX	4.62	0.24	0.24	487455
2025-11-10	RXRX	4.52	0.23	0.35	469226
2025-11-11	RXRX	4.71	0.23	0.16	479456
2025-11-12	RXRX	4.66	0.23	0.46	484390
2025-11-13	RXRX	4.33	0.23	0.31	486625
2025-11-14	RXRX	4.16	0.24	0.20	486351
2025-11-17	RXRX	4.15	0.23	0.49	473916
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	RXRX	6.68	-10.9	-	-1.59
2025-10-21	RXRX	6.10	-10.9	-	-1.59
2025-10-22	RXRX	5.75	-10.9	-	-1.59
2025-10-23	RXRX	5.72	-10.9	-	-1.59
2025-10-24	RXRX	6.04	-10.9	-	-1.59
2025-10-27	RXRX	6.29	-10.9	-	-1.59
2025-10-28	RXRX	5.91	-10.9	-	-1.59
2025-10-29	RXRX	5.88	-10.9	-	-1.59
2025-10-30	RXRX	5.65	-10.9	-	-1.59
2025-10-31	RXRX	5.52	-10.9	-	-1.59
2025-11-03	RXRX	5.43	-10.9	-	-1.59
2025-11-04	RXRX	4.98	-10.9	-	-1.59
2025-11-05	RXRX	4.95	-10.9	-	-1.59
2025-11-06	RXRX	4.61	-12.3	-	-1.62
2025-11-07	RXRX	4.62	-12.3	-	-1.62
2025-11-10	RXRX	4.51	-12.3	-	-1.62
2025-11-11	RXRX	4.71	38.4	-	-1.53
2025-11-12	RXRX	4.66	38.4	-	-1.53
2025-11-13	RXRX	4.32	38.4	-	-1.53
2025-11-14	RXRX	4.14	38.4	-	-1.53
2025-11-17	RXRX	4.11	38.4	-	-1.53
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	RXRX	-1.03	-0.81	40.06
2025-10-21	RXRX	-1.03	-0.81	40.06
2025-10-22	RXRX	-1.03	-0.81	40.06
2025-10-23	RXRX	-1.03	-0.81	40.06
2025-10-24	RXRX	-1.03	-0.81	40.06
2025-10-27	RXRX	-1.12	-0.33	37.94
2025-10-28	RXRX	-1.12	-0.33	37.94
2025-10-29	RXRX	-1.12	-0.33	37.94
2025-10-30	RXRX	-1.12	-0.33	37.94
2025-10-31	RXRX	-1.12	-0.33	37.94
2025-11-03	RXRX	-1.12	-0.38	37.94
2025-11-04	RXRX	-1.12	-0.38	37.94
2025-11-05	RXRX	-1.12	-0.38	37.94
2025-11-06	RXRX	-1.16	-0.38	37.94
2025-11-07	RXRX	-1.16	-0.38	37.95
2025-11-10	RXRX	-1.16	-0.12	37.96
2025-11-11	RXRX	-1.17	-0.12	37.96
2025-11-12	RXRX	-0.97	-0.12	32.06
2025-11-13	RXRX	-0.98	-0.12	32.06
2025-11-14	RXRX	-0.98	-0.12	32.06
2025-11-17	RXRX	-0.98	1.27	31.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.33

Avg. EPS Est. Next Quarter

-0.35

Insider Transactions

-0.98

Institutional Transactions

1.27

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

90.4

Max Drawdown 5-Year %

Target Price

6.33

P/E

Forward P/E

PEG

P/S

49.16

P/B

1.94

P/Free Cash Flow

EPS

-1.81

Average EPS Est. Cur. Y

-1.53

EPS Next Y. (Est.)

-1.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1637.81

Relative Volume

0.6

Return on Equity vs Sector %

-95.3

Return on Equity vs Industry %

-80.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.05

EBIT Estimation

Recursion Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 800

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today

news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance

stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market

stock prices RXRX premarket after hours

ticker RXRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RXRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y